Skip to main navigation Skip to search Skip to main content

Prognostic model based on magnetic resonance imaging, whole-tumour apparent diffusion coefficient values and HPV genotyping for stage IB-IV cervical cancer patients following chemoradiotherapy

  • Gigin Lin
  • , Lan Yan Yang
  • , Yu Chun Lin
  • , Yu Ting Huang
  • , Feng Yuan Liu
  • , Chun Chieh Wang
  • , Hsin Ying Lu
  • , Hsin Ju Chiang
  • , Yu Ruei Chen
  • , Ren Chin Wu
  • , Koon Kwan Ng
  • , Ji Hong Hong
  • , Tzu Chen Yen
  • , Chyong Huey Lai*
  • *Corresponding author for this work
  • Chang Gung Memorial Hospital

Research output: Contribution to journalJournal Article peer-review

19 Scopus citations

Abstract

Objectives: To develop and validate a prognostic model of integrating whole-tumour apparent diffusion coefficient (ADC) from pretreatment diffusion-weighted (DW) magnetic resonance (MR) imaging with human papillomavirus (HPV) genotyping in predicting the overall survival (OS) and disease-free survival (DFS) for women with stage IB–IV cervical cancer following concurrent chemoradiotherapy (CCRT). Methods: We retrospectively analysed three prospectively collected cohorts comprising 300 patients with stage IB–IV cervical cancer treated with CCRT in 2007–2014 and filtered 134 female patients who underwent MR imaging at 3.0 T for final analysis (age, 24–92 years; median, 54 years). Univariate and multivariate Cox regression analyses were used to evaluate the whole-tumour ADC histogram parameters, HPV genotyping and relevant clinical variables in predicting OS and DFS. The dataset was randomly split into training (n = 88) and testing (n = 46) datasets for construction and independent bootstrap validation of the models. Results: The median follow-up time for surviving patients was 69 months (range, 9–126 months). Non-squamous cell type, ADC10 <0.77 × 10-3 mm2/s, T3-4, M1 stage and high-risk HPV status were selected to generate a model, in which the OS and DFS for the low, intermediate and high-risk groups were significantly stratified (p < 0.0001). The prognostic model improved the prediction significantly compared with the International Federation of Gynaecology and Obstetrics (FIGO) stage for both the training and independent testing datasets (p < 0.0001). Conclusions: The prognostic model based on integrated clinical and imaging data could be a useful clinical biomarker to predict OS and DFS in patients with stage IB–IV cervical cancer treated with CCRT. Key points: • ADC10is the best prognostic factor among ADC parameters in cervical cancer treated with CCRT • A novel prognostic model was built based on histology, ADC10, T and M stage and HPV status • The prognostic model outperforms FIGO stage in the survival prediction.

Original languageEnglish
Pages (from-to)556-565
Number of pages10
JournalEuropean Radiology
Volume29
Issue number2
DOIs
StatePublished - 01 02 2019

Bibliographical note

Publisher Copyright:
© 2018, European Society of Radiology.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Cervical cancer
  • Chemoradiotherapy
  • Diffusion magnetic resonance imaging
  • Human papillomavirus
  • Prognosis

Fingerprint

Dive into the research topics of 'Prognostic model based on magnetic resonance imaging, whole-tumour apparent diffusion coefficient values and HPV genotyping for stage IB-IV cervical cancer patients following chemoradiotherapy'. Together they form a unique fingerprint.

Cite this